<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68809">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01897740</url>
  </required_header>
  <id_info>
    <org_study_id>A1481307</org_study_id>
    <nct_id>NCT01897740</nct_id>
  </id_info>
  <brief_title>Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil</brief_title>
  <official_title>A Local, Single-Centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy for Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil, Prior To Reimbursement And Availability for Subjects in Russian Federation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide Sildenafil therapy for subjects who completed
      A1481156 study and are judged by the investigator to derive clinical benefit from continued
      treatment with Sildenafil, prior to reimbursement and availability for subjects in the
      Russian Federation.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Pulmonary Arterial Hypertension (PAH)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>tablets of sildenafil 20 mg 3 times a day for subjects with body weight &gt; 20 kg and 10 mg TID for subjects with body weight â‰¤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients Who Completed study A1481156 and Are Judged by the Investigator to Derive
             Clinical Benefit from Continued Treatment with Sildenafil, Prior to Reimbursement and
             Availability for Subjects in Russian Federation.

          -  Child bearing age women should have apropriate contraception.

          -  Signed informed consent. Patients who have a wish and possibility to follow treatment
             regimens in terms of the study.

        Exclusion Criteria:

          -  Pregnant and lactating women.

          -  Participation in other studies in the current moment or during study period except of
             A1481156.

          -  Patients with severe acute or chronic diseases psychiatric disorders or laboratory
             abnormalities.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Moscow research institute of pediatrics and pediatric surgery</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481307&amp;StudyName=Sildenafil%20Therapy%20For%20Subjects%20Who%20Derive%20Clinical%20Benefit%20from%20Continued%20Treatment%20With%20Sildenafil</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sildenafil</keyword>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>PAH</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
